Ferrari R, Raddino R, Ceconi C, Curello S, Ghielmi S, Visioli O
Cattedra di Cardiologia e Cattedra di Chimica, Università degli Studi di Brescia, Italy.
Cardiovasc Drugs Ther. 1989 Jun;3(3):403-12. doi: 10.1007/BF01858111.
To assess whether pretreatment with the calcium antagonist anipamil protects the heart against ischemic and reperfusion damage and to establish how long the protection persists after cessation of the therapy, rabbits were injected subcutaneously twice daily for 5 days with 2 mg/kg body weight of this drug. The heart was then isolated 2, 6, or 12 hours after the last injection and was perfused by the Langendorff technique during a control period and 90 minutes of total ischemia (37 degrees C), followed by 30 minutes of reperfusion. Diastolic and developed pressure was monitored; coronary effluent was collected and assayed for creatine phosphokinase (CPK); mitochondria were harvested and assayed for respiratory activity, ATP production, and calcium content; and tissue concentration of adenosine triphosphate (ATP) and creatine phosphate were determined. The data obtained with anipamil were compared with those obtained with verapamil administered to the rabbit at the same dose and following the same procedure. Pretreatment with anipamil induced a negative inotropic effect under normoxic conditions; reduced the rate and extent of depletion of ATP and creatine phosphate during ischemia, with an incomplete restoration of the nucleotides after reperfusion; maintained mitochondrial function and calcium homeostasis during ischemia and reperfusion; reduced the rate of CPK release; and improved the recovery of ventricular function on reperfusion. The protective effects of anipamil persisted for as long as 12 hours after the last administration. In contrast, the protective and negative inotropic effects of verapamil were no longer apparent in heart isolated 6 or 12 hours after the last dose of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)
为评估钙拮抗剂阿尼帕米预处理是否能保护心脏免受缺血及再灌注损伤,并确定治疗停止后这种保护作用能持续多久,对家兔每日皮下注射两次、连续5天给予2mg/kg体重的该药物。在最后一次注射后2、6或12小时分离心脏,采用Langendorff技术在对照期及90分钟完全缺血(37℃)期间进行灌注,随后再灌注30分钟。监测舒张期和收缩期压力;收集冠状动脉流出液并测定肌酸磷酸激酶(CPK);收获线粒体并测定呼吸活性、ATP生成及钙含量;测定组织中三磷酸腺苷(ATP)和磷酸肌酸的浓度。将阿尼帕米获得的数据与以相同剂量和相同程序给予家兔维拉帕米所获得的数据进行比较。阿尼帕米预处理在常氧条件下产生负性肌力作用;减少缺血期间ATP和磷酸肌酸的消耗速率及程度,再灌注后核苷酸未完全恢复;在缺血及再灌注期间维持线粒体功能和钙稳态;降低CPK释放速率;并改善再灌注时心室功能的恢复。阿尼帕米的保护作用在最后一次给药后长达12小时持续存在。相比之下,维拉帕米的保护作用和负性肌力作用在最后一剂药物后6或12小时分离的心脏中不再明显。(摘要截短于250字)